ABSTRACT
Objective@#To evaluate the concordance of PD-L1 expression in various tissues using antibodies 28-8 and SP263 on their respective detection platforms.@*Methods@#Three hundred seventy four specimens of surgical resection of pulmonary diseases in the First Affiliated Hospital of Nanjing Medical University from January 1, 2012 to January 31, 2017 were collected. Totally 374 cases were tested for PD-L1 expression using the two antibodies, 28-8 and SP263, by respective detection platforms (Dako and Ventana). Finally, 336 cases were used for further evaluation, and the results were statistically analyzed for concordance.@*Results@#For non-small cell lung carcinoma (NSCLC), the positive rate of PD-L1 was 57.5% (177/308) using SP263, and 57.5% (177/308) using 28-8 antibody. The correlation coefficient was 0.97 (P<0.01). The positive rate of both benign lung diseases and paracancerous tissues was about 10.7% (3/28), and the positive concordance rate was 100.0%. The distribution of both antibodies was also relatively consistent.@*Conclusions@#The expression levels of 28-8 and SP263 antibodies in NSCLC and other tissues are relatively consistent, suggesting both antibodies may be complementary and substitute for each other, which may be useful in guiding clinical management.
ABSTRACT
ABSTRACT Autoimmune encephalitis (AIE) is one of the most common causes of noninfectious encephalitis. It can be triggered by tumors, infections, or it may be cryptogenic. The neurological manifestations can be either acute or subacute and usually develop within six weeks. There are a variety of clinical manifestations including behavioral and psychiatric symptoms, autonomic disturbances, movement disorders, and seizures. We reviewed common forms of AIE and discuss their diagnostic approach and treatment.
RESUMO As encefalites autoimunes (EAI) são a principal causa de encefalite não-infecciosa. As manifestações neurológicas são variadas, incluindo alterações comportamentais ou psiquiátricas, disautonomia, transtornos do movimento e epilepsia. Habitualmente a instalação dos sintomas ocorre em até 6 semanas, de forma aguda ou subaguda. As EAI podem ser desencadeadas por tumores, quadros infecciosos virais ou ainda apresentar etiologia criptogênica. Este artigo revisa as principais EAI, estratégias de diagnóstico e tratamento.
Subject(s)
Humans , Male , Female , Encephalitis/diagnosis , Encephalitis/therapy , Hashimoto Disease/diagnosis , Hashimoto Disease/therapy , Diagnosis, Differential , Encephalitis/etiology , Encephalitis/physiopathology , Hashimoto Disease/etiology , Hashimoto Disease/physiopathology , Anti-N-Methyl-D-Aspartate Receptor Encephalitis/complications , ImmunotherapyABSTRACT
Early identification and diagnosis of hepatocellular carcinoma (HCC) is necessary for improving survival rates of HCC patients. Studies have shown that the abnormal proteins released by tumor cells, i.e., the autoantibodies stimulated by tumor-associated antigens (TAAs), can be detected before a clinical diagnosis of HCC is made, and therefore, such proteins may become the new markers for the early diagnosis of HCC. This article reviews the application of several new autoantibodies to tumor-associated antigens in the diagnosis of HCC and points out that these autoantibodies have promising prospects and clinical significance in the early diagnosis of HCC.
ABSTRACT
Paraneoplastic neurological syndromes (PNS) were defined as neurological syndromes associated with cancer.In many cases,autoantibodies against neural antigens expressed by the tumor (paraneoplastic neurological antibody or onconeural antibodies) were detected.The neuronal antibodies,which were associated with syndromes resulting from central nervous system neuronal dysfunction,were classified into two groups according to the location of the antigen:inside the neuron or in the cell membrane.Group Ⅰ antibodies targeted on intracellular antigens and were predominantly dependent on T-cell-mediated responses.Group Ⅱ antibodies recognized neuronal surface antigens and were predominantly dependent on B-cell-mediated responses.Onconeural antibodies were useful diagnostic markers of the brain disease,and in some cases,they might reveal an underlying malignancy.Moreover,the presence of antibodies against surface(group Ⅱ) antigens might predict a more favorable response to immunotherapy than that against intracellular (group Ⅰ) antigens.
ABSTRACT
CONTEXT: Splenic marginal zone lymphoma (SMZL) is a lymphoproliferative B-cell disorder that has a favorable prognosis, with estimated overall five-year survival of 70 percent. The majority of symptomatic patients undergo splenectomy, while a few receive first-line chemotherapy, especially with purine analogues. There are no specific treatment guidelines for patients for whom splenectomy fails to provide a cure. It is still unclear whether these patients should undergo cytotoxic chemotherapy, considering they have now a relapsed lymphoma (which is theoretically more aggressive), or whether they should be spared from treatments of greater toxicity, given that their disease usually develops with a more indolent course, even when it recurs. CASE REPORT: Here, we present two patients whose disease recurred after splenectomy and for whom rituximab monotherapy provided satisfactory treatment. From these cases, it can be suggested that postponement of cytotoxic treatments may be possible in at least some situations. It needs to be emphasized that the evidence to support this approach is based only on case reports, since there are no randomized clinical trials on this subject.
CONTEXTO: Os linfomas da zona marginal esplênicos constituem uma desordem linfoproliferativa de células B que apresenta um prognóstico favorável, com sobrevida global de cinco anos estimada em 70 por cento. A maioria dos pacientes sintomáticos é submetida a esplenectomia enquanto alguns recebem quimioterapia terapêutica de primeira linha, especialmente com análogos de purinas. Não existem diretrizes específicas para o tratamento dos pacientes que falham à esplenectomia: ainda é incerto se deveriam ser tratados com quimioterapia citotóxica, em virtude de apresentarem um linfoma recidivado (e teoricamente mais agressivo) ou se deveriam ser poupados de um tratamento mais tóxico pelo fato de apresentarem uma doença que usualmente se desenvolve de forma mais indolente, mesmo quando recidivada. RELATO DE CASO: Nesta publicação, são apresentados dois casos nos quais a doença recidivou após esplenectomia e que foram satisfatoriamente tratados com monoterapia com rituximabe. A observação desses casos sugere que a postergação de tratamentos citotóxicos pode ser possível pelo menos em algumas situações. Cabe ressaltar que a evidência para essa conduta é embasada apenas em relatos de caso, uma vez que não existem ensaios clínicos randomizados a respeito desse tema.